Discover 2,423 paid clinical trials in Bethesda, Maryland. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
for
Breast Neoplasms
Location: Silver Spring MD, Fairfax VA, Baltimore MD, Richmond VA,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT06312176
Phase 3, Recruiting
Active & Responsive
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
for
Triple Negative Breast Neoplasms
Location: Silver Spring MD, Washington D.C. DC, Olney MD,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT06841354
Phase 3, Recruiting
Active & Responsive
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
for
Platinum-resistant Ovarian Cancer,
Location: Silver Spring MD, Pittsburgh PA, Greenville NC,
Sponsor: Genelux Corporation
Sex: Female
Age: 18+
Code: NCT05281471
Phase 3, Recruiting
Active & Responsive
Measuring the Effects of Netarsudil, Latanoprost, and Combination Therapy on Episcleral and Retinal Blood Flow in Ocular Hypertension and Glaucoma Suspects
for
Ocular Hypertension, Suspect Glaucoma
Location: Silver Spring MD, Columbia MD, Baltimore MD
Sponsor: University of Maryland, Baltimore
Sex: All
Age: 18+
Code: NCT04401982
Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Active & Responsive
Prospective Outcomes Study: Vectra® DA Guided Care Compared to Usual Care
for
Arthritis, Rheumatoid
Location: Wheaton MD, Arlington VA, Burke VA, Lewes DE,
Sponsor: Crescendo Bioscience
Sex: All
Age: 18 - 70+
Code: NCT02832297
Recruiting
Active & Responsive
ALTO-207 in Adults With Treatment-resistant Depression (TRD)
for
Treatment-resistant Depression (TRD)
Location: Rockville MD, Fairfax VA, Pikesville MD, Toms River NJ,
Sponsor: Alto Neuroscience
Sex: All
Age: 18 - 70+
Code: NCT07553637
Phase 2, Recruiting
Active & Responsive
Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention
for
Percutaneous Coronary Intervention,
Location: Takoma Park MD, Silver Spring MD, Rockville MD,
Sponsor: Duke University
Sex: All
Age: 18+
Code: NCT06909565
Phase 4, Recruiting
Active & Responsive
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
for
Advanced Esophageal Adenocarcinoma,
Location: Washington D.C. DC, Newark DE, Mechanicsburg PA,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT06203600
Phase 2, Phase 3, Recruiting
Active & Responsive
Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer
for
Metastatic Colorectal Adenocarcinoma,
Location: Washington D.C. DC, Baltimore MD, Atlanta GA, Aurora CO
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT07147231
Phase 1, Phase 2, Recruiting
Active & Responsive
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
for
Extensive Stage Lung Small Cell Carcinoma,
Location: Washington D.C. DC, Baltimore MD, Charlottesville VA,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT06287775
Phase 1, Phase 2, Recruiting
Active & Responsive
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
for
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer,
Location: Washington D.C. DC, Fairfax VA, Baltimore MD,
Sponsor: Astellas Pharma Global Development, Inc.
Sex: All
Age: 18+
Code: NCT06901531
Phase 3, Recruiting
Active & Responsive
Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer
for
Carcinoma, Non-Small Cell Lung
Location: Washington D.C. DC, Baltimore MD
Sponsor: Georgetown University
Sex: All
Age: 18+
Code: NCT04499053
Phase 2, Recruiting
Active & Responsive
HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease
for
Huntington's Disease
Location: Washington D.C. DC, Baltimore MD, Toronto, Ottawa,
Sponsor: University College, London
Sex: All
Age: 11 - 70+
Code: NCT02855476
Recruiting
Active & Responsive
A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
for
Huntington Disease
Location: Washington D.C. DC, Baltimore MD, Richmond VA,
Sponsor: Novartis Pharmaceuticals
Sex: All
Age: 21 - 70
Code: NCT07326709
Phase 3, Recruiting
Active & Responsive
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
for
PIK3CA Mutation, HER2- Negative Breast Cancer,
Location: Washington D.C. DC, Fairfax VA, Baltimore MD, Newark DE,
Sponsor: Relay Therapeutics, Inc.
Sex: All
Age: 18+
Code: NCT06982521
Phase 3, Recruiting
Active & Responsive
A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
for
Atopic Dermatitis
Location: Rockville MD, Pittsburgh PA, New York NY, Boardman OH,
Sponsor: Apogee Therapeutics, Inc.
Sex: All
Age: 18+
Code: NCT07003425
Phase 2, Recruiting
Active & Responsive
Prospective US Radiofrequency SUI Trial
for
Urinary Incontinence, Stress
Location: Washington DC, Owings Mills MD, Philadelphia PA,
Sponsor: Viveve Inc.
Sex: Female
Age: 18+
Code: NCT04720352
Recruiting
Active & Responsive
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
Location: Washington D.C. DC, Baltimore MD, Martinsburg WV,
Sponsor: National Cancer Institute (NCI)
Sex: Female
Age: 18+
Code: NCT07198074
Phase 3, Recruiting
Active & Responsive
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
for
Recurrent Head and Neck Squamous Cell Carcinoma,
Location: Washington D.C. DC, Columbia MD, Glen Burnie MD,